Compare
Unicycive Therapeutics, Inc. vs Vistagen Therapeutics, Inc. vs Coya Therapeutics, Inc. vs NextCure, Inc.
| Latest fiscal year | Unicycive Therapeutics, Inc. UNCY | Vistagen Therapeutics, Inc. VTGN | Coya Therapeutics, Inc. COYA | NextCure, Inc. NXTC |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-03-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $1.27M | $7.95M | n/a |
| Revenue growth (YoY) | n/a | +161.1% | +123.6% | n/a |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/m | -283.9% | n/a |
| Net margin | n/a | n/m | -267.1% | n/a |
| Net income | -$26.55M | -$69.69M | -$21.23M | -$55.84M |
| EPS (Diluted) | -$1.67 | -$1.83 | -$1.27 | -$19.65 |
| Operating cash flow | -$31.32M | -$66.44M | -$10.74M | -$49.61M |
| Free cash flow | -$31.34M | n/a | n/a | n/a |
| Cash & equivalents | $29.20M | $30.79M | $46.82M | $25.98M |
| Total assets | $49.13M | $48.56M | $49.95M | $50.18M |
| Total liabilities | $18.94M | $13.04M | $6.92M | $15.24M |
| Shareholders' equity | $30.20M | $35.52M | $43.03M | $34.94M |
| Return on year-end equity | -87.9% | -196.2% | -49.3% | -159.8% |
| Shares outstanding | 22.11M | n/a | 20.93M | 3.51M |
Revenue, most recent five fiscal years
| Fiscal year | Unicycive Therapeutics, Inc. | Vistagen Therapeutics, Inc. | Coya Therapeutics, Inc. | NextCure, Inc. |
|---|---|---|---|---|
| Latest | $675.0K Ended 2023-12-31 | $1.27M Ended 2026-03-31 | $7.95M Ended 2025-12-31 | $22.38M Ended 2020-12-31 |
| 1 year earlier | $951.0K Ended 2022-12-31 | $486.0K Ended 2025-03-31 | $3.55M Ended 2024-12-31 | $6.35M Ended 2019-12-31 |
| 2 years earlier | n/a | $1.06M Ended 2024-03-31 | $6.00M Ended 2023-12-31 | n/a |
| 3 years earlier | n/a | n/a | $0 Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $1.11M Ended 2022-03-31 | n/a | n/a |